Clinical Trials Logo

Multiple Sclerosis clinical trials

View clinical trials related to Multiple Sclerosis.

Filter by:

NCT ID: NCT06231030 Recruiting - Multiple Sclerosis Clinical Trials

Unidimensional Self-Efficacy Scale for Multiple Sclerosis (USE-MS) Turkish Adaptation

Start date: November 5, 2023
Phase:
Study type: Observational [Patient Registry]

Multiple Sclerosis (MS) is a chronic, inflammatory, demyelinating, autoimmune disease of the central nervous system. Despite functional limitations and unpredictable disease course, individuals with MS are aimed to maintain different levels of independence according to the level of disability. It is aimed to develop interventions that aim to increase self-efficacy levels and participation in daily life in individuals with this diagnosis. The "Unidimensional Self-Efficacy Scale for Multiple Sclerosis (USE-MS)" is a self-efficacy scale developed specifically for individuals with MS and answered based on patient declaration. The aim of this study is to adapt the "USE-MS" scale into Turkish and to establish its validity and reliability.

NCT ID: NCT06228781 Not yet recruiting - Multiple Sclerosis Clinical Trials

Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis

Start date: December 1, 2024
Phase: N/A
Study type: Interventional

Autologous hematopoietic stem cell transplantation (aHSCT) is the only treatment for refractory autoimmune diseases capable of inducing long-term, drug-free and asymptomatic remission. Over the past two decades, aHSCT has been used to treat inflammatory autoimmune disease of the CNS. Patients with relapsing-remitting multiple sclerosis benefit from aHSCT treatment. However, a certain percentage of patients still experience recurrence 3 or 5 years after transplantation. Therefore, exploration of conditioning regimens will drive therapeutic advances in aHSCT in autoimmune diseases of the CNS.

NCT ID: NCT06226831 Recruiting - Multiple Sclerosis Clinical Trials

Onset of Lower Urinary Tract Symptoms in Multiple Sclerosis Patients

Start date: June 1, 2020
Phase:
Study type: Observational

Retrospective, non-interventional case-control study, the patients were asked about their first lower-urinary tract symptoms and the date of their onset, using a structured interview. The information was matched with the medical records.

NCT ID: NCT06223074 Enrolling by invitation - Methylprednisolone Clinical Trials

Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration

IN-DXM-EMRR
Start date: January 9, 2023
Phase: Phase 2
Study type: Interventional

This Clinical Trial evaluates the nasal administration of Methylprednisolone as a treatment strategy for Acute Relapses in Multiple Sclerosis

NCT ID: NCT06222359 Not yet recruiting - Depression Clinical Trials

Identifying and Managing Psychological Distress in Multiple Sclerosis: The COMPASS-MS Study

Start date: February 2024
Phase:
Study type: Observational

The aim of this pre-post observational study is to explore if it is feasible to implement 1) routine mental health screening and b) an online Cognitive Behavioural Therapy (CBT) treatment for anxiety and/or depression (named COMPASS-MS) for people living with Multiple Sclerosis (MS) (PwMS) and co-morbid psychological distress in routine care.

NCT ID: NCT06221631 Not yet recruiting - Multiple Sclerosis Clinical Trials

BrainAgeMS - a Comparative Study of Brain Aging in Healthy and Patients With Multiple Sclerosis

BrainAgeMS
Start date: June 2024
Phase:
Study type: Observational

The purpose of this study is to investigate new quantitative MRI-sequences for assessment of age-specific data for the prediction of brain aging.

NCT ID: NCT06220669 Recruiting - Multiple Sclerosis Clinical Trials

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

Start date: March 19, 2024
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.

NCT ID: NCT06220409 Completed - Sclerosis, Multiple Clinical Trials

Gut Microbiota Composition, Cognitive Function, and Physical Fitness in Multiple Sclerosis Patients

MSDANCE
Start date: March 1, 2022
Phase: N/A
Study type: Interventional

The evidence suggests that multiple sclerosis (MS) induces a decline in motor and cognitive function and provokes a shift in gut microbiome composition in patients. Therefore, the purpose of this study is to explore the effect of a 12-week dance class training program on the gut microbiota composition, motor function, and cognitive function of patients with MS. The investigators will also study the following: - The impact of organised physical activity on quality of life - The impact of organised physical activity on body composition and metabolic parameters (e.g., insulin sensitivity, lipid profile, ect.) - The impact of organised physical activity on physical fitness (e.g., VO2max, Power, ect.)

NCT ID: NCT06220201 Recruiting - Multiple Sclerosis Clinical Trials

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis

Start date: March 28, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS).

NCT ID: NCT06219304 Recruiting - Multiple Sclerosis Clinical Trials

Effect of High Intensity Training on Motor and Cognitive Functions

FAST
Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Fatigability is one of the most prevalent disorder in MS followed by walking, balance and cognitive disorders. However, there are few experimental studies on the effects of fatigability on balance and gait hampering the knowledge of causal fatigue-related changes of walking, balance and cognition. Nowadays, instrumented systems such as wearable devices and optoelectronic systems are available and can be used to provide quantitative and objective indexes useful to monitor the changes of gait parameters during a fatiguing performance. (Moreover), instrumented assessment of patients' performances in dual task paradigms can reveal the possible impact of fatigability on cognitive functions. So far, high intensity functional training has been already used in MS to reduce fatigability. However, the true impact of reduced fatigability on walking, balance and cognition has not been assessed after a fatiguing task making impossible to understand the real impact of treatments focusing on fatigability on these functions. Thus, the aims of the present proposal are to assess the: 1) the acute effect of experimentally induced motor fatigability on walking, balance and cognitive functions using an objective instrumented assessment before, during, and after an overground fatiguing walking test. 2) to investigate the effect of high intensity multimodal functional training to improve motor and cognitive disorders.